Application Value and Research Frontiers of Immunotherapy in Glioblastoma: A Bibliometric and Visualized Analysis
There has been a growing interest in GBM immunotherapy over past decades. The United States is the dominant contributor. CAR-T therapy represents the primary research focus. Emerging strategies like chimeric antigen receptor-modified natural killer (CAR-NK) cells, chimeric antigen receptor-engineered macrophages (CAR-M), and cytomegalovirus-specific T cell receptor (CMV-TCR) T cells are gaining prominence, aiming to address limitations in antigen recognition inherent to CAR-T therapy for GBM.
Authors
- Mingsheng Lei (ORCID: https://orcid.org/0000-0002-6954-9507)
- Minghua Wu (ORCID: https://orcid.org/0000-0002-6701-8825)
- Kun Deng
- Wei Gao (ORCID: https://orcid.org/0000-0002-0522-7234)
- Danyang Li (ORCID: https://orcid.org/0000-0003-2957-4131)
- Jianliang Huang (ORCID: https://orcid.org/0000-0002-4700-0329)
Institutions
- Central South University (CN)
- Hunan Normal University (CN)
- Ministry of Education (SA)
- Zhangjiakou Academy of Agricultural Sciences (CN)
- Xiangya Hospital Central South University (CN)
Publication Details
- Journal
- Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
- Published
- 2025-11-20
- DOI
- https://doi.org/10.32604/or.2025.069442
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00